• 89% of people living with HIV expressed a preference to switch from daily oral therapy to long-acting injectable Cabenuva

• 89% 的 HIV 感染者表示希望从每日口服治疗转为使用长效注射剂 Cabenuva

OSAKA, Japan, July 24, 2025 -

日本大阪，2025年7月24日 -

Shionogi & Co., Ltd.  (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter 'Shionogi') announced that ViiV Healthcare Ltd. (“ViiV”), in which Shionogi holds equity alongside GlaxoSmithKline plc and Pfizer Inc., has

盐野义制药株式会社（总部：日本大阪；首席执行官：手代木功博士；以下简称“盐野义”）宣布，其与葛兰素史克和辉瑞共同持股的ViiV Healthcare Ltd.（“ViiV”）已

presented

呈现

results from the Phase IIIb VOLITION study of Cabenuva at the 13th International AIDS Society Conference (IAS 2025).

Cabenuva的IIIb期VOLITION研究结果在第13届国际艾滋病学会会议（IAS 2025）上公布。

The VOLITION study was conducted in treatment-naïve adults living with HIV. Following rapid viral suppression with daily oral Dovato (dolutegravir and lamivudine), participants were offered the choice to either continue with Dovato or switch to the long-acting injectable Cabenuva (cabotegravir and rilpivirine)..

VOLITION 研究针对的是未接受过治疗的 HIV 感染成人。在使用每日口服 Dovato（多替拉韦和拉米夫定）实现快速病毒抑制后，参与者可以选择继续使用 Dovato 或转为使用长效注射剂 Cabenuva（卡博特韦和利匹韦林）。

Results showed that 89% (n=129/145) of participants chose to switch to Cabenuva. The most commonly cited reasons were “Not having to worry about missing a dose each day” (80%) and “Not having to carry medication” (68%). These findings highlight the potential of long-acting regimens to improve adherence and overall treatment satisfaction among people living with HIV..

结果显示，89%（n=129/145）的参与者选择改用Cabenuva。最常被提及的原因是“不用每天担心忘记服药”（80%）和“不用随身携带药物”（68%）。这些发现突显了长效方案在改善HIV感染者依从性和整体治疗满意度方面的潜力。

Shionogi has positioned “Protect people from the threat of infectious diseases” as one of its key material issues and is committed to addressing the three major infectious diseases—HIV, tuberculosis, and malaria—through comprehensive initiatives. With over 60 years of experience in infectious disease research and development, Shionogi will continue to work in partnership with ViiV Healthcare to contribute to global health by advancing both treatment and prevention strategies for HIV..

盐野义制药将“保护人类免受传染病威胁”定位为其关键议题之一，并通过综合措施致力于解决艾滋病、结核病和疟疾这三大传染病问题。凭借在传染病研发领域超过60年的经验，盐野义制药将继续与ViiV Healthcare合作，通过推进艾滋病的治疗和预防策略，为全球健康做出贡献。

Reference:

参考：

About Dovato (marketed in Japan as Dovato Combination Tablets)

关于Dovato（在日本市场称为Dovato复合片）

Dovato is a daily oral two-drug regimens containing dolutegravir 50 mg and lamivudine 300 mg. It is approved for the treatment of HIV-1 infection in adults who are either treatment-naïve or virologically suppressed on antiretroviral therapy, with no known resistance to dolutegravir or lamivudine.

Dovato 是一种每日一次的口服两药方案，包含 50 毫克多鲁特格拉韦和 300 毫克拉米夫定。该药物适用于治疗从未接受过治疗或在抗逆转录病毒治疗中病毒学上已得到抑制，且对多鲁特格拉韦或拉米夫定无已知耐药性的成人 HIV-1 感染者。

About Cabenuva (marketed in Japan as Vocabria Intramuscular Suspension and Rekambys® Intramuscular Suspension)

关于Cabenuva（在日本市场称为Vocabria肌肉注射悬浮液和Rekambys®肌肉注射悬浮液）

Cabenuva is the world’s first long-acting injectable for HIV treatment. It is approved in major markets including Japan, the U.S., Europe, and China as a treatment option administered once every two months.

Cabenuva 是全球首款用于 HIV 治疗的长效注射剂。它已在包括日本、美国、欧洲和中国在内的主要市场获得批准，作为每两个月注射一次的治疗选择。

1

1

In addition to the results of this study, multiple real-world data led by ViiV Healthcare—including COMBINE-2, CARLOS, BEYOND, and OPERA—have demonstrated high efficacy, tolerability, and improved adherence, contributing to enhanced treatment satisfaction across a broad range of patient populations..

除了这项研究的结果外，由ViiV Healthcare主导的多项真实世界数据——包括COMBINE-2、CARLOS、BEYOND和OPERA——均显示出高效性、良好的耐受性和依从性改善，从而提升了广泛患者群体的治疗满意度。

2

2

1.

1.

ViiV Healthcare Press Release: February 26, 2024

ViiV Healthcare新闻稿：2024年2月26日

LATITUDE PHASE III INTERIM TRIAL DATA INDICATES ViiV HEALTHCARE’S LONG-ACTING INJECTABLE HIV TREATMENT CABENUVA (CABOTEGRAVIR + RILPIVIRINE) HAS SUPERIOR EFFICACY COMPARED TO DAILY THERAPY IN INDIVIDUALS LIVING WITH HIV WHO HAVE ADHERENCE CHALLENGES

纬度三期中期试验数据显示，ViiV Healthcare公司的长效注射型HIV治疗药物CABENUVA（卡博特韦+利匹韦林）在面临服药依从性挑战的HIV感染者中，相比每日疗法具有更优的疗效。

2.

2.

ViiV Healthcare Press Release: July 14, 2025

ViiV Healthcare新闻稿：2025年7月14日

ViiV HEALTHCARE DATA SHOW 89% OF TREATMENT-NAÏVE PEOPLE WITH HIV CHOOSE TO SWITCH TO LONG-ACTING INJECTABLE VOCABRIA + REKAMBYS FROM DAILY PILLS AFTER ACHIEVING RAPID VIRAL SUPPRESSION

ViiV Healthcare数据显示，89%的初治HIV感染者在实现快速病毒抑制后选择从每日口服药物转换为长效注射药物Vocabria + Rekambys。

Forward-Looking Statements

前瞻性声明

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate.

本公告包含前瞻性陈述。这些陈述是基于当前可获得的信息和预期，而这些假设受到风险和不确定性的制约，可能导致实际结果与这些陈述有重大差异。风险和不确定性包括一般国内和国际经济状况，如一般行业和市场状况，以及利率和汇率的变化。

These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations.

这些风险和不确定性尤其适用于与产品相关的前瞻性声明。产品风险和不确定性包括但不限于临床试验的完成和终止；获得监管批准；对产品安全性和有效性的主张和担忧；技术进步；重要诉讼的不利结果；国内外医疗改革以及法律法规的变更。

Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise..

对于现有产品，也存在生产和营销风险，包括但不限于无法建立满足需求的生产能力、原材料供应不足以及竞争产品的进入。公司否认有任何意图或义务更新或修改任何前瞻性声明，无论是否由于新信息、未来事件或其他原因。

For Further Information, Contact:

如需更多信息，请联系：

SHIONOGI Website Inquiry Form:

盐野义制药网站咨询表：

https://www.shionogi.com/global/en/contact.html

https://www.shionogi.com/global/en/contact.html